A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Latest Information Update: 31 May 2025
At a glance
- Drugs Arlocabtagene autoleucel (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms QUINTESSENTIAL
- Sponsors Juno Therapeutics
Most Recent Events
- 30 Jan 2025 Planned number of patients changed from 150 to 175.
- 13 Jan 2025 Planned End Date changed from 4 Jun 2030 to 30 Jun 2032.
- 13 Jan 2025 Planned primary completion date changed from 2 Oct 2026 to 30 Jun 2027.